Curaleaf (OTCMKTS:CURLF) Shares Down 9.6% – Time to Sell?

Curaleaf Holdings, Inc. (OTCMKTS:CURLF) dropped 9.6% on Friday . The stock traded as low as $3.5401 and last traded at $3.5601. Approximately 591,742 shares traded hands during mid-day trading, a decline of 42% from the average daily volume of 1,024,857 shares. The stock had previously closed at $3.94.

Wall Street Analyst Weigh In

Separately, Zacks Research raised Curaleaf from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, May 5th. Three investment analysts have rated the stock with a Strong Buy rating and one has assigned a Buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Strong Buy”.

Curaleaf Price Performance

The company has a 50-day moving average price of $2.74 and a two-hundred day moving average price of $2.64. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.56 and a quick ratio of 0.74. The company has a market cap of $2.49 billion, a PE ratio of -27.39 and a beta of 1.58.

Curaleaf (OTCMKTS:CURLF) last issued its quarterly earnings results on Tuesday, May 5th. The company reported $0.09 EPS for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.17. The firm had revenue of $324.23 million during the quarter, compared to the consensus estimate of $316.62 million. Curaleaf had a negative return on equity of 8.11% and a negative net margin of 7.76%. Sell-side analysts expect that Curaleaf Holdings, Inc. will post -0.12 earnings per share for the current fiscal year.

About Curaleaf

Curaleaf Holdings, Inc is a leading American cannabis company engaged in the cultivation, processing and distribution of both medical and adult-use cannabis products. Headquartered in Wakefield, Massachusetts, Curaleaf operates cultivation facilities, processing centers and retail dispensaries across multiple U.S. jurisdictions. The company’s vertically integrated model allows it to manage the entirety of its supply chain, from seed to sale, ensuring consistent quality and compliance with stringent regulatory requirements.

Curaleaf’s product portfolio spans a wide range of formats, including premium flower, vaporizer cartridges, edibles, tinctures, topicals and concentrates.